Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Liu, Katherine ^a   Cang, Shundong ^b   Ma, Yuehua ^b   Chiao, Jen Wei ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PHENETHYL ISOTHIOCYANATE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; DRUG POTENTIATION; EPIGENETICS; HUMAN; HUMAN CELL; IN VIVO STUDY;

EID: 84873336329     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-10     Document Type: Article

References (49)

1. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 1999, 286(5439):481-486. 10.1126/science.286.5439.481, 10521337.
2. Ura K, Kurumizaka H, Dimitrov S, Almouzni G, Wolffe AP. Histone acetylation: influence on transcription, nucleosome mobility and positioning, and linker histone-dependent transcriptional repression. EMBO J 1997, 16(8):2096-2107. 10.1093/emboj/16.8.2096, 1169812, 9155035.
3. Workman JL, Kingston RE. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 1998, 67:545-579. 10.1146/annurev.biochem.67.1.545, 9759497.
4. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 1999, 99(5):451-454. 10.1016/S0092-8674(00)81532-9, 10589672.
5. Hendrich B, Bird A. Mammalian methyltransferases and methyl-CpG-binding domains: proteins involved in DNA methylation. Curr Top Microbiol Immunol 2000, 249:55-74. 10.1007/978-3-642-59696-4_4, 10802938.
6. Tyler JK, Kadonaga JT. The " dark side" of chromatin remodeling: repressive effects on transcription. Cell 1999, 99(5):443-446. 10.1016/S0092-8674(00)81530-5, 10589670.
7. Tse C, Sera T, Wolffe AP, Hansen JC. Disruption of higher-order folding by core histone acetylation dramatically enhances transcription of nucleosomal arrays by RNA polymerase III. Mol Cell Biol 1998, 18(8):4629-4638. 109049, 9671473.
8. Wade PA. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet 2001, 10(7):693-698. 10.1093/hmg/10.7.693, 11257101.
9. Momparler RL. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). Semin Oncol 2005, 32(5):443-451. 10.1053/j.seminoncol.2005.07.008, 16210084.
10. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005, 11(10):3604-3608. 10.1158/1078-0432.CCR-04-2135, 15897554.
11. Kelly WK, Richon VM, O'Connor O, Curley T, Gregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9(10 Pt 1):3578-3588.
12. Beklemisheva AA, Fang Y, Feng J, Ma X, Dai W, Chiao JW. Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res 2006, 26(2A):1225-1230.
13. Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, Feng J, Liu D, Chiao JW. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 2008, 33(2):375-380.
14. Wang LG, Beklemisheva A, Liu XM, Ferrari AC, Feng J, Chiao JW. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol Carcinog 2007, 46(1):24-31. 10.1002/mc.20258, 16921492.
15. Zou Y, Ma X, Huang Y, Hong L, Chiao J-W. Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia. J Hematol Oncol 2012, 5(1):36. 10.1186/1756-8722-5-36, 3413588, 22747680.
16. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993, 85(11):892-897. 10.1093/jnci/85.11.892, 8492317.
17. Xu B, Wu Y, Shen L, Ye D, Jappe A, Cherfi A, Wang H, Yuan R. Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. J Hematol Oncol 2011, 4(1):3. 10.1186/1756-8722-4-3, 3032760, 21232120.
18. Yuan Y, Liao Y-M, Hsueh C-T, Mirshahidi H. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011, 4(1):16. 10.1186/1756-8722-4-16, 3103487, 21504625.
19. Rafiyath S, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol 2012, 1(1):10. 10.1186/2162-3619-1-10, 3514106, 23210520.
20. Elbaz H, Stueckle T, Tse W, Rojanasakul Y, Dinu C. Digitoxin and its analogs as novel cancer therapeutics. Exp Hematol Oncol 2012, 1(1):4. 10.1186/2162-3619-1-4, 3506989, 23210930.
21. WeiSZ L, Efferth T. Polo-like kinase 1 as target for cancer therapy. Exp Hematol Oncol 2012, 1(1):38. 10.1186/2162-3619-1-38, 3533518, 23227884.
22. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991, 83(24):1797-1805.
23. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von HD. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991, 9(7):1261-1267.
24. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989, 111(4):273-279. 10.7326/0003-4819-111-4-273, 2569287.
25. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. JAm Chem Soc 1971, 93(9):2325-2327.
26. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987, 47(9):2486-2493.
27. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987, 5(8):1232-1239.
28. Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JK, Tormey DC, Swaminathan S, Trump DL. Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 1987, 71(12):1179-1184.
29. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987, 71(12):1171-1177.
30. Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007, 7(8):730-742. 10.2174/156800907783220417, 18220533.
31. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 1981, 256(20):10435-10441.
32. Fuchs DA, Johnson RK. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978, 62(8):1219-1222.
33. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980, 77(3):1561-1565. 10.1073/pnas.77.3.1561, 348536, 6103535.
34. Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. Biochemistry 1981, 20(11):3247-3252. 10.1021/bi00514a041, 6113842.
35. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277(5698):665-667. 10.1038/277665a0, 423966.
36. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A 1995, 92(10):4507-4511. 10.1073/pnas.92.10.4507, 41973, 7753834.
37. Cang S, Feng J, Konno S, Han L, Liu K, Sharma SC, Choudhury M, Chiao JW. Deficient histone acetylation and excessive deacetylase activity as epigenomic marks of prostate cancer cells. Int J Oncol 2009, 35:1417-1422.
38. Lu L, Liu D, Ma X, Beklemishev A, Seiter K, Ahmed T, Chiao JW. The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Oncol Rep 2006, 16(6):1363-1367.
39. Lu Q, Lin X, Feng J, Zhao X, Gallagher R, Lee MY, Chiao JW, Liu D. Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol 2008, 1:6. 10.1186/1756-8722-1-6, 2438442, 18577263.
40. Ma X, Fang Y, Beklemisheva A, Dai W, Feng J, Ahmed T, Liu D, Chiao JW. Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol 2006, 28(5):1287-1293.
41. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981, 115(1):207-216.
42. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006, 10(3):241-252. 10.1016/j.ccr.2006.08.009, 16959615.
43. Lamba G, Gupta R, Lee B, Ambrale S, Liu D. Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol 2012, 1(1):14. 10.1186/2162-3619-1-14, 3514103, 23210689.
44. Firer M, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol 2012, 5(1):70. 10.1186/1756-8722-5-70, 3508879, 23140144.
45. Guo Y, Chen Y, Xu X, Fu X, Zhao Z. SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells. J Hematol Oncol 2012, 5(1):72. 10.1186/1756-8722-5-72, 3524753, 23216927.
46. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012, 1(1):36. 10.1186/2162-3619-1-36, 3520838, 23210908.
47. Badia E, Oliva J, Balaguer P, Cavailles V. Tamoxifen resistance and epigenetic modifications in breast cancer cell lines. Curr Med Chem 2007, 14(28):3035-3045. 10.2174/092986707782794023, 2789301, 18220739.
48. Munster PN, Lacevic M, Schmitt M, Bicaku E, Marchion D, Stephens A, Sullivan L, Minton S. Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy. J Clin Oncol 2008, 26:abs#3501.
49. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 1993, 68(6):1104-1109. 10.1038/bjc.1993.488, 1968657, 7903152.